365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment

BACKGROUND: Fostemsavir (FTR), the prodrug of the first-in-class attachment inhibitor temsavir, is indicated in combination with other antiretrovirals (ARVs) for heavily-treatment experienced (HTE) people with multidrug-resistant HIV-1 unable to construct suppressive regimens. After ∼5 years in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyson, Alftan, Aberg, Judith A, Molina, Jean-Michel, Cassetti, Isabel, Kozal, Michael, Treviño-Pérez, Sandra, Latiff, Gulam, Lalezari, Jacob, Pialoux, Gilles, Li, Bo, Prakash, Manyu, Clark, Andrew, Tenorio, Allan R, Pierce, Amy, Lataillade, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676856/
http://dx.doi.org/10.1093/ofid/ofad500.435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676856/
http://dx.doi.org/10.1093/ofid/ofad500.435

Ejemplares similares